Pregnancy comes with unique health risks and considerations, but pregnant people also continue to experience the same health ...

Stryker is selling off its spine implant business—starting with a plan to spin off its U.S. operations before moving on to ...

Trouble sleeping is common in other neurodegenerative diseases, but past research has only suggested that it occurs in ...

Mab’s pipeline pivot had a sting in the tail. Weeks after shifting its focus, the biotech said Wednesday that it has reduced ...

Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...

The FDA’s move to lift the hold on Zentalis Pharmaceuticals’ sole clinical-stage drug may have been good news for the biotech ...

Zimmer Biomet is taking steps to expand its foot and ankle orthopedics business, with a $1.1 billion deal to acquire the ...

Just days after President Trump imposed broad restrictions on communications, meetings, travel and public appearances at the ...

Demand slipped for several large contract research organizations last year, and a new report from William Blair analysts ...

A judge has ruled against investor Alcon Research on the matter of blocking investee Aurion Biotech from debuting on the ...

Having shown last week that its opioid alternative can reduce post-surgery pain, Tris Pharma is back with another slice of ...

Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset ...